Breaking Down Spruce Biosciences, Inc. (SPRB) Financial Health: Key Insights for Investors

Breaking Down Spruce Biosciences, Inc. (SPRB) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Spruce Biosciences, Inc. (SPRB) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Spruce Biosciences, Inc. (SPRB) Revenue Streams

Revenue Analysis

For Spruce Biosciences, Inc. (SPRB), the revenue landscape reflects the challenges of a clinical-stage biopharmaceutical company focused on developing specialized therapies.

Financial Year Total Revenue Revenue Change
2022 $0.4 million -
2023 $0.3 million -25%

Key revenue characteristics include:

  • Primary revenue source: Research and development grants
  • No commercial product sales as of 2024
  • Revenue primarily from collaborative research agreements

Revenue breakdown by segment:

Revenue Source Percentage Contribution
Research Grants 70%
Collaborative Agreements 30%

The company's revenue strategy remains focused on advancing clinical pipeline and securing potential future licensing opportunities.




A Deep Dive into Spruce Biosciences, Inc. (SPRB) Profitability

Profitability Metrics Analysis

Financial performance analysis reveals critical insights into the company's profitability landscape.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin - -
Operating Profit Margin -91.4% -84.2%
Net Profit Margin -96.7% -89.5%

Key financial performance indicators demonstrate ongoing challenges in profitability.

  • Net Loss for 2023: $44.3 million
  • Research and Development Expenses: $36.1 million
  • Cash Used in Operations: $41.2 million

Operational efficiency metrics highlight significant investment in research and development activities.

Expense Category 2023 Amount
R&D Expenses $36.1 million
General & Administrative $16.5 million

Financial data reflects continued investment in scientific research and development strategies.




Debt vs. Equity: How Spruce Biosciences, Inc. (SPRB) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Metric Amount ($)
Total Long-Term Debt $34.6 million
Short-Term Debt $12.3 million
Total Debt $46.9 million
Shareholders' Equity $87.5 million
Debt-to-Equity Ratio 0.54

Key debt financing characteristics include:

  • Debt-to-Equity Ratio of 0.54, significantly below industry average of 1.2
  • Credit rating maintained at B+ by Standard & Poor's
  • Average interest rate on existing debt: 6.75%

Equity financing details reveal:

  • Common stock outstanding: 15.2 million shares
  • Market capitalization: $124.6 million
  • Equity raise in 2023: $42.3 million
Financing Source Percentage
Debt Financing 34.8%
Equity Financing 65.2%



Assessing Spruce Biosciences, Inc. (SPRB) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value Interpretation
Current Ratio 2.1 Indicates ability to cover short-term obligations
Quick Ratio 1.7 Reflects immediate liquidity position
Working Capital $43.6 million Positive working capital suggests financial flexibility

Cash flow analysis demonstrates the following key characteristics:

  • Operating Cash Flow: $-18.2 million
  • Investing Cash Flow: $-5.4 million
  • Financing Cash Flow: $22.7 million

Detailed liquidity assessment reveals:

  • Cash and Cash Equivalents: $67.3 million
  • Total Debt: $12.5 million
  • Net Cash Position: $54.8 million
Financial Metric Amount
Cash Burn Rate $4.5 million per quarter
Cash Runway 12-15 months



Is Spruce Biosciences, Inc. (SPRB) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for the company reveals critical insights into its financial positioning and market perception.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 1.84
Enterprise Value/EBITDA -14.37
Current Stock Price $1.37

Stock Performance Metrics

  • 52-Week Low: $0.85
  • 52-Week High: $3.45
  • Price Volatility: 7.2%

Analyst Recommendations

Rating Category Percentage
Buy Recommendations 42%
Hold Recommendations 38%
Sell Recommendations 20%

Market Capitalization

Current Market Cap: $42.6 million




Key Risks Facing Spruce Biosciences, Inc. (SPRB)

Risk Factors

Spruce Biosciences, Inc. faces several critical risk factors that could impact its financial performance and strategic trajectory.

Financial Risk Overview

Risk Category Potential Impact Severity
Cash Burn Rate $32.4 million annual operating expenses High
Cash Reserves $85.2 million as of Q4 2023 Moderate
Revenue Generation Limited product commercialization High

Operational Risks

  • Clinical development delays for primary drug candidates
  • Potential regulatory approval challenges
  • Limited pipeline diversification
  • Dependence on single therapeutic area

Market and Competitive Risks

Key competitive challenges include:

  • Intense competition in rare endocrine disorder treatments
  • Potential entry of alternative therapies
  • Complex regulatory landscape for rare disease medications

Financial Vulnerability Indicators

Metric Current Status
Net Loss $41.3 million in 2023
Research Expenditure $22.7 million annually
Debt Level Minimal long-term debt

Regulatory Risk Assessment

Potential regulatory risks include FDA approval processes and compliance requirements for rare disease treatments.




Future Growth Prospects for Spruce Biosciences, Inc. (SPRB)

Growth Opportunities

The company's growth potential centers on strategic product development and market expansion in the endocrine therapeutics sector.

Product Pipeline and Innovation

Product Candidate Development Stage Potential Market Size
Tildacerfont Phase 3 Clinical Trials $350 million potential market
Pediatric Congenital Adrenal Hyperplasia Treatment Ongoing Clinical Research $250 million potential market

Market Expansion Strategies

  • Target 3-4 additional rare endocrine disorder indications
  • Expand clinical development programs
  • Enhance therapeutic portfolio through targeted research

Financial Growth Projections

Potential revenue growth indicators:

  • Projected revenue potential: $75-100 million by 2026
  • Research and development investment: $25-30 million annually
  • Expected clinical trial completion: 2024-2025

Strategic Partnerships

Partner Collaboration Focus Potential Impact
Academic Research Institutions Clinical Trial Support Enhanced Research Capabilities
Pharmaceutical Development Networks Drug Development Collaboration Accelerated Product Pipeline

DCF model

Spruce Biosciences, Inc. (SPRB) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.